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Introduction
RA is a chronic inflammatory disease characterized by
articular cartilage and bone destruction. The pathogenesis
of inflammation and tissue destruction in RA results from
complex cell–cell interactions between, among others,
T lymphocytes, monocytes and synoviocytes [1–3].
The contribution of the pro-inflammatory macrophage-
derived cytokines IL-1 and tumor necrosis factor (TNF)-a
has been well established through their capacity to modu-
late cartilage and bone metabolism. On the one hand, IL-1
and TNF-a stimulate osteoblasts to secrete cytokines
such as granulocyte–monocyte colony stimulating factor
(GM-CSF) and IL-6, which in turn regulate osteoclast
formation. This leads, or not, to osteoclastic bone resorp-
tion according to the local conditions [4–6]. Chondrocyte
activation similarly contributes to cartilage matrix destruc-
tion. On the other hand, IL-1 and TNF-a suppress matrix
synthesis in cartilage and inhibit collagen synthesis in
osteoblasts, leading to defective repair [7,8]. These two
molecules are now, accordingly, the main targets for treat-
ment, and the use of blocking anti-TNF-a antibodies,
soluble TNF-a receptors and IL-1 receptor antagonist has
shown very interesting clinical results, including protective
effects on cartilage and bone [9–12].
The role of T cells and their derived cytokines on these cell
interactions inside the synovium has also been the subject
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of a number of studies. A growing list of factors from
T cells, including IL-7, IL-18, GM-CSF, TNF-a and, more
importantly, RankL has similarly been shown to act on bone
remodeling [6,13–15]. As T cells are present in bone
marrow, their local contribution is probable. It has long
been thought that, in cartilage, cytokines would act only by
diffusion. Direct cell contact may, however, occur during
the invasion of cartilage by the tumor-like synoviocytes.
Recent information regarding the contribution of T cells
through their cytokines has come from results with IL-17.
This cytokine is exclusively produced by activated T cells
[16]. Furthermore, bioactive IL-17 is produced by RA syn-
ovium [17,18]. As IL-17 shares properties with IL-1 and
TNF-a, it may affect both osteoclast and chondrocyte-
mediated resorption, and thereby mediate bone and carti-
lage destruction [19,20]. Whether IL-17 produced by RA
synovium affects bone by diffusion or whether IL-17 pro-
duced locally by juxta-articular bone is also a mediator of
bone destruction remains to be clarified.
The aim of the present study was to assess the role of
IL-17, used alone and in association with IL-1, in the
inflammatory and destructive pattern characteristic of RA,
by looking at its effects on synovium, cartilage and bone.
Through the use of IL-17 inhibitors, we then looked at the
respective contribution of IL-17 produced by synovium
and bone. Finally, intra-articular administration of IL-17
was performed to study its direct effect on destruction.
Materials and methods
Cytokines and reagents
Dr Fossiez (Schering-Plough Research Center, Dardilly,
France) kindly provided human recombinant IL-17 and
anti-IL-17 monoclonal antibody (mAb) 5. One microgram
per milliliter of mAb5 was able to completely inhibit the
IL-6 production by synoviocytes induced by 50 ng/ml
IL-17, whereas an irrelevant mAb had no effect [21]. This
antibody had no effect on the action of IL-1, TNF-a, GM-
CSF, and monocyte-CSF. Human recombinant IL-1b
( 2×1 0 8 U/mg) was purchased from Sigma Chemical Co
(St Louis, MO, USA). Murine soluble IL-17 receptor
(sIL-17R) was kindly provided by Dr Kendall Mohler
(Immunex, Seattle, WA, USA), the properties of which
have been previously described [22]. One microgram per
milliliter of sIL-17R was able to completely inhibit the IL-6
production by synoviocytes induced by 50 ng/ml IL-17,
whereas normal human IgG used as control for the fusion
IgG–Fc part had no effect (data not shown).
Preparation of synovium and bone explant cultures
Synovium and bone samples were obtained from patients
with RA, according to the revised criteria of the American
College of Rheumatology [23], who were undergoing
knee or wrist synovectomy, or joint replacement. Synovium
and bone fragments were prepared as already described
[24,25]. These samples show prolonged and active
cytokine production and bone resorption, related to the
persistence of active osteoclasts. Samples were cut into
small pieces of approximately 2 mm3, and incubated in
triplicate in complete medium made of MEM medium
(Gibco, Grand Island, NY, USA), 2 mM L-Glutamin,
100 U/ml penicillin, 50 mg/ml gentamicin, 20 mM Hepes
buffer and 1% fetal calf serum. Synovium and bone frag-
ments were cultured in 24-well plates (Falcon, Oxnard,
CA, USA) in a final volume of 2 ml. The cytokines or IL-17
inhibitors to be tested were added at the beginning of the
culture. Cultures were performed at 37°C in a 5%
CO2/95% humidified air. Supernatants were collected at
day 7 in order to measure the accumulation of effects
related to the cytokine cascade.
Measurement of type I collagen degradation in human
samples
Type I collagen C-telopeptide breakdown products (CTX)
were measured in synovium piece culture supernatants by
a two-site enzyme-linked immunosorbent assay (ELISA)
(Serum Crosslaps one step™; Osteometer Biotech®,
Ballerup, Denmark) using two monoclonal antibodies
raised against a synthetic peptide with an amino acid
sequence specific for a part of the C-telopeptide of the
a1-chain of type I collagen [26]. Intra-assay and inter-assay
coefficients of variation are lower than 5 and 8%, respec-
tively, and the sensitivity is 154 pmol/l.
Determination of human type I collagen production in
human samples
The production of type I collagen was estimated in culture
media by measuring the concentration of the C-pro-
peptide of type I collagen (PICP) using a two-site ELISA,
which uses a monoclonal and a polyclonal antibody raised
against human PICP purified from skin fibroblast cultures
(Procollagen-CTM; Metra Biosystem, Inc, Palo Alto, CA,
USA) [27]. The sensitivity of the assay is 1 ng/ml, and the
intra-assay and inter-assay coefficients of variation are less
than 7%.
Determination of IL-6 levels by ELISA
ELISA measured IL-6 levels as previously described [28].
Briefly, supernatants or serial dilutions of IL-6 standard
(Schering-Plough Research Institute, Kenilworth, NJ, USA)
were incubated for 60 min at 37°C in 96-well microtiter
plates (Nunc, Roskilde, Denmark) coated overnight at 4°C
with the mouse 39C3 anti-IL-6 mAb (1 mg/ml), and satu-
rated for 60 min at 20°C with phosphate buffered saline
5% bovine albumin. Biotinylated mouse MQ2 anti-IL-6
mAb (1 mg/ml) was added after washing and the mixture
incubated for 60 min at 20°C. The plates were read at
492 nm after subsequent incubation with peroxidase
streptavidin and revelation with orthophenylenediamine
(Sigma Chemical Co). The sensitivity of the assay was
150 pg/ml.Arthritis Research    Vol 3 No 3 Chabaud et al
Cartilage tissue culture
Patellae obtained from C57B/1 mice, aged 10–12 weeks,
were dissected in a standardized manner from the knee
joint as previously described [29]. Specimens were cul-
tured in 200 ml RPMI 1640 (Dutch modification), with glu-
tamic acid (2 mM) and 0.1% bovine serum albumin at
37°C in a humidified 5% CO2 atmosphere. In addition,
0.25 mg human recombinant insulin-like growth factor
(IGF-1) was added to provide optimal metabolic activity of
chondrocytes [30]. Explants were cultured in the pres-
ence of murine recombinant IL-1 and/or IL-17 (R&D
system, Minneapolis, MN, USA). Determination of the syn-
thesis rate and release of cartilage proteoglycan (PG)
turnover was performed after culture for 48 h in the pres-
ence of cytokines.
Determination of mouse chondrocyte proteoglycan
synthesis
As a measurement for PG synthetic activity of chondro-
cyte, the sulfate incorporation rate into PG was deter-
mined as previously described [29]. This rate was
calculated from the 35SO4
2– incorporation and the specific
activity of the medium. After culture in the presence of
cytokines, specimens were pulse-labeled with 35S-sulfate
(20 mCi/ml) for three additional hours. The specimens
were thereafter washed three times, fixed in 4% formalin
and subsequently decalcified in formic acid (5%) for 4 h.
The patellar cartilage was punched out of adjacent tissue
and dissolved in 0.5 ml Lumasolve (Omnilabo, Breda, The
Netherlands). The 35S-sulfate incorporation label was
measured by scintillation counting.
Determination of mouse cartilage proteoglycan
breakdown
Patellae were pulse-labeled with 35S-sulfate for 3 h before
exposure to cytokines. After three washes with medium,
patella specimens were cultured for an additional 48 h in
the presence of IGF-1 (0.25 mg/ml) and/or the various
combinations of IL-1 and IL-17. Cultures were performed
with six patella specimens per variable, and the data are
expressed as mean values ± SD relative to the values
found with IGF-1 alone.
Intra-articular injection of IL-17
Recombinant murine IL-17 (100 ng/ml) alone was injected
into the joint space of the right knee of naive C57Bl/6
mice at days 0 and 3. The contra-lateral joint received an
equal volume (6 ml) of saline. Mice were killed by cervical
dislocation 2 days after the last injection. Whole knee
joints were thereafter removed and fixed for 4 days in 10%
formalin. Specimens were processed for paraffin embed-
ding after decalcification in 5% formic acid. Tissue sec-
tions (7 mm) were stained with hematoxylin and eosin, and
Safranin O. Proteoglycan depletion was determined using
Safranin O staining.
Statistical analysis
Results were expressed as mean ± SEM of the indicated
number of experiments. Statistical evaluation was per-
formed with the nonparametric Wilcoxon paired t test.
Results
Effect of IL-17 on IL-6 production by RA synovium
explants
An ex vivo model of RA synovitis has been established
using synovium pieces obtained at surgery [24]. Since
RA synovium is composed of different cell types, we
tested how IL-17, a T-cell product, would regulate the
production of IL-6 and we compared its effect with that of
IL-1. Thus synovium pieces were incubated with and
without 50 ng/ml IL-17 and/or with and without
100 pg/ml IL-1. Levels of IL-6 were measured after 7
days of culture. IL-17 increased spontaneous IL-6 pro-
duction (mean ± SEM, 202 ± 57 ng/ml) by 64 ± 17%
(Fig. 1). IL-1 also increased spontaneous IL-6 production
by 90 ± 27%. The combination of IL-17 and IL-1 induced
a 189% increase of IL-6 production.
Effect of IL-17 on type I collagen metabolism in
synovium explants
To investigate the consequences of addition of exogenous
IL-17, we measured its effect on the destruction/formation
activity of type I collagen by synovium explants. First, syn-
thesis of type I collagen in synovium cultures was analyzed
by measuring the release of PICP in supernatants by
ELISA. Spontaneous production of PICP was
371 ± 36 ng/ml (range, 334–442 ng/ml). IL-17 inhibited
these levels by a mean of 38% and inhibited IL-1 by a
mean of 23% (n = 3; Fig. 2a).
Second, to assess the degradation of type I collagen from
these synovium explants, we measured levels of CTX, a
C-terminal peptide released during degradation of type I
collagen. Spontaneous production of CTX was 33 ± 11 nM
(range, 3–77 nM). IL-17 enhanced CTX release by 211%,
an effect that was as potent as that of IL-1 (274%) (Fig. 2b).
These results combined indicated a dual effect of IL-17 on
synovium, leading to increased destruction and reduced for-
mation of type I collagen.
Effect of IL-17 on cartilage proteoglycan synthesis and
degradation
The second important target in a joint is cartilage. There
are, however, serious limitations to using the same type of
ex vivo model with samples of cartilage obtained during
joint surgery in RA. Only limited amounts of cartilage could
obviously be obtained that way. To assess such an impor-
tant target, we switch to a mouse model where patellae are
cultured ex vivo in the presence of exogenous cytokines.
First, we examined the capacity of IL-17 to inhibit chondro-
cyte PG synthesis. Whole patellae were incubated with
IL-17 and/or IL-1 for 48 h under IGF-1 stimulation, whichinduced an optimal synthesis of PG. Addition of IL-17 and
IL-1 inhibited this synthesis by 23 and 40%, respectively
(Table 1). The combination of IL-17 and IL-1 was more
potent, inhibiting PG synthesis by 63%.
Second, we looked at the effects of IL-17 and IL-1 on PG
release. PG release during cartilage culture with
cytokines was enhanced by 22% with 100 ng/ml IL-17,
and by 25% with 10 ng/ml IL-1 (Fig. 3). Combination of
IL-17 and IL-1 was more potent, increasing PG loss by
35%. Our results show that inhibition of PG synthesis by
IL-17 was accompanied by PG breakdown, indicating
that IL-17 induced cartilage degradation and suppression
of its synthesis. These results combined also indicate a
dual effect of IL-17 on cartilage, increasing PG break-
down and decreasing its synthesis.
Effect of IL-17 on IL-6 production by RA bone explants
Finally, the third target to consider was bone because RA
leads to early juxta-articular bone loss. Regarding the
origin of cytokines affecting bone, cytokines produced by
synovium can reach bone by diffusion or be released by
the bone microenvironment itself. IL-6 has been shown to
favor osteoclastogenesis. An ex vivo model of bone
resorption was established to investigate the effect of
IL-17 on IL-6 release by bone using bone pieces obtained
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Figure 1
Effect of exogenous IL-17 on IL-6 production by RA synovium.
Synovium samples from RA patients were incubated for 7 days in the
presence of IL-17 (50 ng/ml; n = 10), IL-1 (100 pg/ml; n = 10), and
IL-17 + IL-1 (n = 3). ELISA measured IL-6 levels in supernatants.
Results are expressed as mean ± SEM of % induction of IL-6
production. Spontaneous production of IL-6 was 202 ± 57 ng/ml. 
* P < 0.01, ** P < 0.05 compared with control (medium alone).
Figure 2
Effect of exogenous IL-17 on type I collagen metabolism in RA synovium
explants. Synovium samples from RA patients were incubated for 7 days
in the presence of IL-17 (50 ng/ml) or IL-1 (100 pg/ml). (a) PICP (n = 4)
levels in supernatants were measured by ELISA. Results are expressed
as mean ± SEM of % induction of PICP production. Spontaneous
production of PICP was 371 ± 36 ng/ml. (b) CTX levels (n = 7) in
supernatants were measured by ELISA. Results are expressed as mean
± SEM. Spontaneous production of CTX was 33 ± 11 ng/ml. 
* P < 0.05, ** P < 0.01 compared with control (medium alone).
Table 1
IL-17 inhibits mouse chondrocyte proteoglycan (PG) synthesis
Culture conditiona
IGF-1 IL-1 IL-17 Chondrocyte PG synthesis (%)b
+ – – 100 ± 11
+ + – 58 ± 5*
+–+ 6 6   ± 8*
+++ 4 0   ± 5*
a Mouse patellae incubated with insulin-like growth factor (IGF-1) (0.25
mg/ml), and with and without IL-1 (1 ng/ml), IL-17 (10 ng/ml), or IL-1
and IL-17 for 48 h. b Values represent percentages of sulfate
incorporation into proteoglycans ± SD of four separate experiments
with six mice per group per experiment. * P < 0.01 compared with IGF-
1 alone, by Wilcoxon rank sum test.at the site of joint surgery of patients with RA as previously
described [25]. Bone pieces were incubated, as for syn-
ovium pieces, with and without 50 ng/ml IL-17 and/or with
and without 100 pg/ml IL-1. IL-17 increased the sponta-
neous production (220 ± 95 ng/ml) of IL-6 by these bone
pieces by 41 ± 25% and that of IL-1 by 73 ± 21% (Fig. 4).
The combination of IL-17 and IL-1 had a much larger
effect on IL-6 production (171 ± 55%).
Effect of IL-17 on type I collagen metabolism in bone
explants
IL-17 and/or IL-1 were, as already shown, able to induce
collagen degradation and, more importantly, to decrease
collagen synthesis by synovium and cartilage. It was impor-
tant to extend these results to bone collagen. We thus
tested how IL-17 would regulate collagen synthesis/degra-
dation balance using this model. Samples of RA bone were
incubated in the presence or absence of IL-17 and/or IL-1.
First, we investigated the consequences of IL-17 on collagen
synthesis by measuring the release of PICP by bone explants.
The spontaneous production of PICP was 433 ± 133 ng/ml
(range, 299–567 ng/ml). IL-17 inhibited such production
by 42 ± 10% and IL-1 by 21 ± 3% (Fig. 5a).
We then analyzed the effect of IL-17 on type I collagen
degradation by measuring CTX release in bone culture
supernatants. Spontaneous release of CTX by bone culture
was variable (104 ± 55 nM; range, 8–331 nM). IL-17
increased this release by 110% and IL-1, being less potent,
by 11% (Fig. 5b). The combination of IL-1 and IL-17 had a
synergistic effect increasing CTX release by 257%. As
shown for synovium and then cartilage, IL-17 was also able
to increase bone destruction and reduce its formation.
Contribution of bone-derived endogenous
IL-17 to destruction
Regarding the two possible mechanisms of bone destruc-
tion in RA (ie diffusion of cytokines derived from synovium
or production by juxta-articular bone), we looked at the
contribution of endogenous IL-17 produced first by RA
synovium and then by RA bone explants with specific
IL-17 inhibitors. When RA synovium explants were incu-
bated with sIL-17R or with an anti-IL-17 mAb (mAb5),
spontaneous CTX production was inhibited in a same
fashion by 75 and 88%, respectively (n = 5; Fig. 6a).
Previous studies regarding the in situ bone environment
have demonstrated that juxta-articular bone itself can
produce as many cytokines as the inflamed synovium from
the same joint [25]. This was first described for cytokines
produced by monocytes and mesenchymal cells such as
IL-6 and leukemia inhibitory factor. To look at the potential
contribution of bone-derived T-cell cytokines, namely IL-17,
we performed similar blocking experiments with bone cul-
tures. The sIL-17R was added at the onset of bone culture,
and CTX release in supernatants was analyzed by ELISA.
Results show that sIL-17R could reduce CTX release by a
mean of 64% in bone cultures (Fig. 6b). Paired samples of
bone and synovium were available from the same joint for
Arthritis Research    Vol 3 No 3 Chabaud et al
Figure 4
Effect of exogenous IL-17 on IL-6 production by RA bone explants.
Bone samples from RA patients were incubated for 7 days in the
presence of IL-17 (50 ng/ml; n = 5), IL-1 (100 pg/ml; n = 5), and IL-17
+ IL-1 (n = 2). ELISA measured IL-6 levels in supernatants. Results are
expressed as mean ± SEM of % induction of IL-6 production.
Spontaneous production of IL-6 was 220 ± 95 ng/ml. 
* P < 0.05 compared with control (medium alone).
Figure 3
Effect of exogenous IL-17 on mouse cartilage proteoglycan
breakdown. Cartilage explants of patellae were pulse-labeled with
35S-sulfate for 3 h and incubated with IGF-1 (0.25 mg/ml), with or
without IL-17 (10 or 100 ng/ml) and/or IL-1 (10 ng/ml) for 48 h.
Cultures were performed with six patellae per variable, and data
represent percentages of sulfate incorporation into proteoglycan ± SD
relative to the values found with IGF-1 alone.two patients. These samples, as shown in Figure 7, indicated
a much higher rate of collagen destruction in bone when
compared with synovium. More importantly, sIL-17R induced
a very profound reduction of CTX release by bone pieces
(134.2 ± 63.7 ng/ml without versus 45.5 ± 8.8 ng/ml with
sIL-17R; P< 0.05). Similar results were obtained with syn-
ovium pieces (12.6 ± 0.2 ng/ml without sIL-17R versus
4.6 ± 0.8 ng/ml with sIL-17R; P< 0.05). These final results
demonstrate the direct contribution of endogenous IL-17 to
synovium and, moreover, to bone destruction in RA. They
suggest, in particular, that a T-cell subset secreting IL-17
inside bone can contribute significantly to bone destruction.
Intra-articular administration of murine rIL-17 leads to
joint degradation
To extend these results to an in vivo situation, murine
IL-17 was injected into mouse knee joints. We used
normal mice to investigate solely the direct contribution of
IL-17. Whole knee sections were stained for cartilage pro-
teoglycan content. Figure 8 shows that profound proteo-
glycan depletion was observed in the IL-17 treated group
when compared with the control group. These findings
extend the catabolic effects of IL-17 on cartilage degrada-
tion to the in vivo situation.
Discussion
The clinical problem with RA is not only chronic joint
inflammation, but also moreover progressive destruction
Available online http://arthritis-research.com/content/3/3/168
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Figure 5
Effect of exogenous IL-17 on type I collagen metabolism by RA bone
explants. Bone samples from RA patients were incubated for 7 days in
the presence of IL-17 (50 ng/ml) and/or IL-1 (100 pg/ml). (a) PICP
levels (n = 3) in supernatants were measured by ELISA. Results are
expressed as mean ± SEM of % induction of PICP production.
Spontaneous production of PICP was 433 ± 133 ng/ml. (b) CTX levels
in supernatants were measured by ELISA. Bone samples were
incubated with IL-17 (n = 5), IL-1 (n = 5), and IL-17 + IL-1 (n = 2).
Results are expressed as mean ± SEM. Spontaneous production of CTX
was 104 ± 55 ng/ml. * P < 0.05 compared with control (medium alone).
Figure 6
Effect of blockade of endogenous IL-17 on synovium and bone
destruction. (a) Synovium (n = 5) and (b) bone explants (n = 3) from
RA patients were incubated for 7 days with and without blocking anti-
IL-17 mAb (10 mg/ml) or sIL-17R (1 mg/ml), which was added at the
onset of the culture. CTX levels after 7 days of culture were measured
by ELISA. Results are expressed as mean ± SEM of culture triplicates.
Differences between IL-17 inhibitor treated groups and control groups
were analyzed with the nonparametric Wilcoxon paired t test.* P < 0.05.of cartilage and bone. IL-1 and TNF-a are considered the
leading factors in RA that drive the enhanced production
of cytokines, chemokines and degradative enzymes [9].
The definition of IL-17 as a pro-inflammatory T-cell
derived cytokine produced by RA synovium has lead to
the hypothesis that such a cytokine could also be
involved in joint destruction. We have accordingly ana-
lyzed the role of IL-17 in the inflammation and destruction
patterns associated with RA.
IL-17 shares many properties with IL-1 and TNF-a. The
three cytokines activate the common transcription factor
NF-kB in a variety of cell types. They all stimulate stromal
cells such as dermal and synovial fibroblasts, endothelial
cells and epithelial cells to secrete IL-6, IL-8 and PGE2
[16,21,31]. Interactions between these three cytokines
further amplify these effects. IL-17 induces IL-1 and TNF-a
production by human macrophages [32]. Monocyte activa-
tion, conversely, induces Th1 cell differentiation through
IL-12 production, and IL-12 increases IL-17 production by
T cells as shown with T-cell clones [33]. More importantly,
combination of IL-17 with IL-1 or TNF-a often leads to syn-
ergistic or additive effects, which further increase their bio-
logical effects. The present study demonstrates the
potency of IL-17, often similar to that of IL-1, to induce
inhibition of type I collagen synthesis by synovium and
bone, but also of PG synthesis by cartilage. As Th1 cells
infiltrate RA synovium, IL-17 produced by some of these
Th1 cells can increase IL-1 and TNF-a production,
enhancing the rate of degradation and lack of repair,
which are characteristics of RA. Conversely, in osteoarthri-
tis, where the contribution of T cells is less pronounced,
destruction occurs but collagen synthesis is not as
strongly inhibited. The presence of T cells, more precisely
Arthritis Research    Vol 3 No 3 Chabaud et al
Figure 7
Respective contribution of endogenous IL-17 to synovium and bone
destruction. Paired bone and synovium pieces from the same joint in
two RA patients were cultured for 7 days in the presence of sIL-17R 
(1 mg/ml). CTX production in supernatants was measured by ELISA,
and results are expressed in nanomoles.
Figure 8
Effect of intra-articular administration of IL-17 on cartilage destruction.
Naive C57Bl/6 mice were intra-articulately injected into the knee joint
with recombinant murine IL-17 (100 ng/ml) at days 0 and 3 (b and d).
The contralateral joint received an equal volume (6 ml) of saline (a and c).
Knee joints were taken for histology 2 days after the last injection.
Proteoglycan depletion was analyzed using Safranin O staining.
Cartilage depletion was visualized by diminished staining of the matrix.
The effect of IL-17 can be seen as the lighter (b and d) rather than the
darker staining (a and c) in cartilage. (a) and (b), Original magnification,
× 50; (c) and (d), original magnification × 200. P, Patella; F, femur; 
JS, joint space; C, cartilage.of Th1 cells, appears to be linked to defective repair when
comparing the two conditions.
Inflammation and tissue destruction in RA synovium result
from complex cell–cell interactions. Interactions between
antigen presenting cells and CD4+ T cells lead to
macrophage activation and secretion of IL-1 and TNF-a
[2,34]. These factors stimulate matrix degradation collagen
in synovium, cartilage and bone. Similar results were
obtained with IL-17 on induction of matrix metalloproteinase-
1 production by synoviocytes and collagenase activity by
synovium [35]. The present study extends these results by
showing an enhanced effect when combined with IL-1.
Cartilage destruction is a major consequence of chronic
synovitis. At an early stage, cytokines and other soluble
factors acting on chondrocytes most probably induce such
a process by diffusion. At a later stage, proliferation and
activation of synovial cells lead to pannus formation that
invades and destroys cartilage. Previous studies have
demonstrated that cartilage degradation is largely depen-
dent on IL-1 and TNF-a. We show in this paper that carti-
lage degradation can also be induced by IL-17 inhibiting
PG synthesis and increasing its destruction. IL-17 has also
already been shown to induce nitric oxide and stromelysin
expression by isolated chondrocytes [36,37]. Administra-
tion of IL-17 into normal knee was, more importantly, able
to induce such degradation [38]. It is important to notice
that such effect was observed using IL-17 alone and not in
an inflamed joint where IL-1, TNF-a and IL-17 would have
been already present. The endogenous secretion of IL-17
from cartilage appears unlikely and was not evaluated as
IL-17 is still considered a T-cell specific cytokine.
The major contribution of this work is the demonstration of
the role of IL-17 and thus of T cells from bone in destruction
and defective formation. This was shown using specific IL-
17 inhibitors. The important inhibition observed when block-
ing IL-17 alone can be explained by the synergistic
interaction between IL-17 and other cytokines, as first
shown with fibroblasts and synoviocytes [16,21]. Th2 cell
cytokines such as IL-4 have conversely been shown to
inhibit osteoclastogenesis. In a previous study using the
same model, we showed that exogenous IL-4 was able to
decrease bone destruction through an inhibitory effect on
osteoclast survival [25]. In keeping with the Th classification
of cytokines, IL-17 appears to have the opposite effect in
providing signals for osteoclast activity leading to increased
bone destruction and reduced formation. This extends the
results in the mouse showing a defective formation with IL-
17 [19,20]. Previous studies have already demonstrated the
direct contribution of T cells to osteoclast differentiation
through cell contacts with osteoclasts [39]. T cells were
shown to express RankL in particular [6,40]. Furthermore,
this activator of osteoclast formation and activation is also
present in RA synovium [41,42]. Administration of IL-4 in
the mouse model of collagen arthritis was able to control
cartilage and bone destruction through an inhibition of the
expression of IL-1, TNF-a, IL-17 and RankL [43].
Osteoclasts are specialized cells with the capacity of
resorbing bone, whereas osteoblastic stromal cells are
responsible for matrix formation. Bone formation is regu-
lated by an event referred to as the coupling of formation
to resorption, which is mediated in part by locally pro-
duced growth factors. Because of the intimate relationship
between bone marrow cells and bone-specific cells,
marrow cells and their products contribute to the bone
microenvironment and influence the regulation of bone cell
differentiation and activity. In the context of RA, early juxta-
articular bone loss appears to result from in situ bone acti-
vation. Results with paired samples have shown a much
higher level of destruction in bone compared with the syn-
ovium. It appears now that juxta-articular bone can
produce bone-resorbing cytokine(s) from a subset of pro-
inflammatory Th1 cells. These results obtained ex vivo in
man extend those obtained in the mouse, which showed a
direct effect of IL-17 on bone resorption [19].
The present data have significant implication for the thera-
peutic control of joint damage during inflammation. We
could downregulate type I collagen degradation in both
synovium and bone using specific IL-17 inhibitors. As
IL-17 can increase IL-1 and TNF-a production by
macrophages, blocking IL-17 will also decrease IL-1 and
TNF-a actions. Furthermore, combining inhibitors of IL-17
with those of IL-1 and TNF-a may lead to a better effect.
IL-17 may accordingly represent a target of interest for the
treatment of RA, particularly to reduce its consequences
on destruction.
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